Literature DB >> 17065006

Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development.

Jian-Miao Liu1, Jérôme Bignon, Vesna Ilic, Cecilia Briscoe, Jean-Yves Lallemand, Andrew Riches, Joanna Wdzieczak-Bakala.   

Abstract

Evidence from clinical and laboratory studies suggests that angiogenesis is important in the progression of solid tumours and hematologic malignancies. We have shown that the naturally occurring tetrapeptide Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a potent angiogenic factor normally present at nanomolar concentrations in the blood. A murine leukemia model was used to assess whether there was a correlation between levels of endogenous AcSDKP and the development of disease. Levels of AcSDKP in the plasma and bone marrow (BM) cells from mice bearing an acute myeloid leukemia (AML) were five- to ten-fold greater than those in non-leukemic mice. Furthermore, a strong correlation between the concentration of endogenous AcSDKP and the progression of AML was demonstrated. These results are consistent with the marked increase in BM vascularity observed in leukemic mice. The physiologic relevance of these findings awaits further studies and the contribution of AcSDKP to the pathogenesis of leukemia is under investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065006     DOI: 10.1080/10428190600688131

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

2.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 3.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

4.  AcSDKP is down-regulated in anaemia induced by Trypanosoma brucei infection in mice.

Authors:  Janelisa Musaya; Enock Matovu; Edward Senga; Moffat Nyirenda; John Chisi
Journal:  Malawi Med J       Date:  2017-09       Impact factor: 0.875

5.  Prolyl endopeptidase activity is correlated with colorectal cancer prognosis.

Authors:  Gorka Larrinaga; Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Maider Beitia; María C Etxezarraga; Alberto Loizate; Javier Gil; Jon Irazusta; José I López
Journal:  Int J Med Sci       Date:  2014-01-10       Impact factor: 3.738

6.  Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.

Authors:  Enrico Conte; Evelina Fagone; Elisa Gili; Mary Fruciano; Maria Iemmolo; Maria Provvidenza Pistorio; Daniela Impellizzeri; Marika Cordaro; Salvatore Cuzzocrea; Carlo Vancheri
Journal:  Oncotarget       Date:  2016-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.